Attached files
file | filename |
---|---|
EX-10.1 - MATERIAL CONTRACTS - Cellular Biomedicine Group, Inc. | cbmg_ex101.htm |
8-K - CURRENT REPORT - Cellular Biomedicine Group, Inc. | cbmg_8k.htm |
Exhibit 99.1
Cellular Biomedicine Group Obtained NCI Patent License for Next
Generation Neoantigen-Reactive Tumor Infiltrating Lymphocyte (TIL)
Technology to Treat Solid Tumors
SHANGHAI, China and CUPERTINO, Calif., Oct. 03, 2018 (GLOBE
NEWSWIRE) -- Cellular Biomedicine
Group Inc.
(NASDAQ:CBMG) (“CBMG”
or the “Company”), a clinical-stage biopharmaceutical
firm engaged in the development of immunotherapies for cancer and
stem cell therapies for degenerative diseases, today announced it
has entered into a Patent License Agreement (the “License
Agreement”) with the National Cancer Institute
(“NCI”), an institute of the National Institutes of
Health, within the Department of Health and Human Services.
Pursuant to the License Agreement, NCI granted CBMG a
non-exclusive, sub-licensable worldwide license to develop,
manufacture and commercialize next generation neoantigen-reactive
tumor infiltrating lymphocyte (“TIL”) technology to
treat a variety of cancers.
“We are extremely pleased to finalize this License Agreement
as this next generation TIL technology will fortify our clinical
development pipelines for solid tumors. It is a significant
extension of our CAR/TCR-T pipelines against solid tumors in the
immuno-oncology platform,” stated Tony (Bizuo) Liu, Chief
Executive Officer of CBMG. “The medical oncology community is
very aware of the innovative work using T cell-based immunotherapy
and autologous TIL transfer for the treatment of various cancers.
We look forward to continuing to advance this
field.”
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG)
develops proprietary cell therapies for the treatment of cancer and
degenerative diseases. We conduct immuno-oncology and stem cell
clinical trials in China using products from our integrated GMP
laboratory. Our GMP facilities in China, consisting of 12
independent cell production lines, are designed and managed
according to both China and U.S. GMP standards. Our Shanghai
facility includes a “Joint Laboratory of Cell Therapy”
with GE Healthcare and a “Joint Cell Therapy Technology
Innovation and Application Center” with Thermo Fisher
Scientific, whose partnerships focus on improving manufacturing
processes for cell therapies. The CBMG pipeline includes
preclinical compounds targeting CD20-, CD22- and B-cell maturation
antigen (BCMA)-specific CAR-T compounds, and T-cell receptor (TCR)
and tumor infiltrating lymphocyte (TIL) technologies. A Phase IIb
trial in China for Rejoin® autologous Human
Adipose-derived Mesenchymal Progenitor Cell (haMPC) for the
treatment of Knee Osteoarthritis (KOA) as well as a Phase I trial
in China for AlloJoin™ (CBMG's “Off-the-Shelf”
haMPC) for the treatment of KOA are ongoing. CBMG is included in
the broad-market Russell 3000® Index and the small-cap Russell
2000® Index, and the Loncar China BioPharma index. To learn
more about CBMG, please visit www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
trends, specific activities or investments, and other statements
that are not descriptions of historical facts and may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include those
regarding our ability to implement our plans, strategies and
objectives for future operations, including regulatory approval of
our IND applications, our plan to configure part of our Shanghai
facility with GE Healthcare's FlexFactory platform, our ability to
execute on our obligations under the terms of our licensing and
collaboration arrangement with Novartis, our ability to execute on
proposed new products, services or development thereof, results of
our clinical research and development, regulatory infrastructure
governing cell therapy and cellular biopharmaceuticals, our ability
to enter into agreements with any necessary manufacturing,
marketing and/or distribution partners for purposes of
commercialization, our ability to seek intellectual property rights
for our product candidates, competition in the industry in which we
operate, overall market conditions, any statements or assumptions
underlying any of the foregoing and other risks detailed from time
to time in CBMG's reports filed with the Securities and Exchange
Commission, quarterly reports on form 10-Q, current reports on form
8-K and annual reports on form 10-K. Forward-looking statements may
be identified by terms such as “may,”
“will,” “expects,” “plans,”
“intends,” “estimates,”
“potential,” or “continue,” or similar
terms or the negative of these terms. Although CBMG believes the
expectations reflected in the forward-looking statements are
reasonable, they cannot guarantee that future results, levels of
activity, performance or achievements will be obtained. CBMG does
not have any obligation to update these forward-looking statements
other than as required by law.
Contacts:
Sarah Kelly
Director of Corporate Communications, CBMG
+1 408-973-7884
sarah.kelly@cellbiomedgroup.com